Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Naldemedine probably leads to higher laxation response: risk of spontaneous rescue‐free bowel… compared with placebo (moderate certainty).
1 finding from 1 review
Laxation response: patient assessment of change in bowel status at the end of trial · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptoms of opioid withdrawal in the medium term · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
It is very uncertain whether naldemedine changes symptoms of opioid withdrawalein the medium termc compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse eventsh · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Naldemedine showed no clear difference in serious adverse eventsh compared with placebo (low certainty).
1 finding from 1 review
Adverse events · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Naldemedine probably leads to higher adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Symptoms of opioid withdrawal in the medium term · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine showed no clear difference in symptoms of opioid withdrawalfin the medium termb compared with higher doses (low certainty).
1 finding from 1 review
Serious adverse eventsg · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine showed no clear difference in serious adverse eventsg compared with higher doses (low certainty).
1 finding from 1 review
Adverse events · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine showed no clear difference in adverse events compared with higher doses (low certainty).
1 finding from 1 review
Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine may leads to lower laxation response: risk of spontaneous rescue‐free bowel movements… compared with higher doses (low certainty).
1 finding from 1 review
Laxation response: patient assessment of change in bowel status at the end of trial · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found